Background/Aims: Herbal materials derived from Juniperus communis (JCo) possess anticancer activity. In this study, we evaluated the efficacy of a JCo berry extract in suppressing glioblastoma growth. Methods: The effects of JCo extract on the viability of normal and glioma cell lines was analyzed using a modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The synergistic therapeutic effect of JCo extract and temozolomide (TMZ) on glioma cells was examined by MTT analysis. Flow cytometry analysis, the terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) test, and western blotting were performed to identify the apoptotic pathway. To determine the in vivo efficacy of the JCo extract, rats were injected with 5 × 10 4 rat glioma RG2 cells in the back skin and brain hemisphere and then received a subcutaneous injection in the back skin that contained either JCo extract or vehicle. Finally, blood and histologic examinations were performed to evaluate JCo toxicity. Results: The IC 50 values of JCo extract were 57-69 µg/mL and 49-67 µg/mL in the glioblastoma cell lines after 24 and 48 h, respectively. However, in non-tumor cell lines, the respective IC 50 values of JCo extract were 76-105 µg/mL and 77-108 µg/mL. The JCo extract had a stronger cytotoxicity and a larger range of IC 50 values in glioma than in normal cells as compared to those effects caused by temozolomide (TMZ). In addition, the results of flow cytometry analysis, TUNEL test, and western blotting revealed that the JCo extract induced glioma cell cycle arrest through intrinsic and extrinsic apoptotic pathways. In the in vivo studies, a significant reduction of tumor size in JCo-treated rats, as measured by animal MRI, demonstrated that the JCo extract effectively inhibited glioma cell growth and successfully penetrated the blood-brain barrier. The immunohistochemical (IHC) staining detected positive signals of PCNA, VEGFR-1, and VEGFR -2 in 44.49%, 5.88%, and 5.85% of JCo-treated glioma cells, respectively. However, positive signals of PCNA, VEGFR-1, and VEGFR-2 were detected in 73.08%, 9.67%, and 11.70% of vehicle-treated glioma cells, respectively. The IHC examination of PCNA and VEGFR-1 and -2 indicated that JCo extract significantly decreased the degree of neovascularization. However, no significant differences in serum levels of blood cell count and hepatic enzymes, renal function index, and the histologic appearance of vital organs were detected between the JCo and vehicle-treated rats. Conclusion: The JCo extract penetrated the blood-brain barrier and significantly induced glioma cell apoptosis by reducing neovascularization via suppression of the PI3K/AKT/mTOR pathway. Furthermore, JCo extract was less cytotoxic to non-neoplastic vital organs than TMZ.
Introduction
Between 2008 and 2012, the number of primary central nervous system (CNS) tumor incidences was approximately 28.57 per 100, 000 people in the United States [1] . In children and adolescents, primary CNS tumors have the highest incidence and mortality rates. Although meningioma is the most common type and accounts for more than half of primary brain tumors (PBTs) [1] , approximately 80% of malignant PBTs are gliomas. Glioblastoma accounts for 46 .3% of all malignant gliomas and has the poorest prognosis. Surgical intervention combined with radiotherapy and chemotherapy are the standard treatments for glioblastoma [2] . The complications of radiotherapy and chemotherapy include neurotoxicity, cognitive disturbance, radionecrosis, and secondary malignancy [3, 4] . A recently developed therapeutic, temozolomide (TMZ), acts as an alkylating agent which causes DNA damage and induces tumor apoptosis [5] . The combination of irradiation and chemotherapy has become the principally therapeutic strategy for high-grade gliomas. Recent reports indicated that O 6 -methylguanine-DNA methyltransferase (MGMT) promotor unmethylation and long non-coding RNA MALAT1 expression may result in a reduced efficacy of the TMZ treatment [6, 7] . In addition, TMZ has side effects that induce ineffective marrow functions, including neutropenia-related syndrome, thrombocytopenia, and lymphopenia [8] . Recently, immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4, have demonstrated the ability to block the progression of glioma cells [9] . A potential risk of immunotherapy might be the induction of immune cell dysregulation, which increases the possibility of encephalitis [9] . Several studies have proposed to use traditional Chinese medicine for the treatment of PBTs [10] [11] [12] [13] .
Medicinal herbs provide alternative therapies for several human diseases. The pharmaceutical effects of medicinal herbs include anti-inflammatory [14] , antibiotic [15] , and immunoregulatory activities [16] . In recent studies, extracts from several types of plants, such as lichens, Juniperus, and Angelica, were proven to be effective against brain tumor cell progression and angiogenesis [17] [18] [19] . More than half of the pharmaceutical herbal therapeutics are extracted from natural dietary plants, which have fewer side effects than other chemotherapeutic agents [20] . However, the applications of herbal medicine in cancer treatment remain limited by certain disadvantages [21] . Firstly, plant extracts contain many compounds that are often difficult to purify. The interactions between these compounds may lead to unpredictable herbal drug effects. Furthermore, as the underlying mechanisms of some herbal therapeutics are still unknown, discrepancies in cytotoxic effects observed during in vitro and in vivo studies also restricts the extended use of medicinal herbs. Finally, it is difficult to use herbal therapeutics for suppressing brain tumor growth because of the blood-brain barrier (BBB). Therefore, the development of herbal therapeutics with improved penetration through the BBB and strong cytotoxicity to brain tumors might offer an effective therapeutic option for patients with glioblastoma multiforme (GBM).
Juniperus communis (JCo) is a high-altitude plant that grows in south-western Asia and North America [22] . Some alkaloids, flavonoids, glycosides, tannins, phenolic compounds, and steroids from JCo berries and leaves can be extracted using chloroform and methanol [23] . The pharmacological activities of these chemical constituents include anti-inflammatory [24, 25] , antifungal [26] , analgesic [27] , hepatoprotective [23] , antimicrobial, anti-mycobacterial [28, 29] , and neuroprotective [22] effects. In a recent study, Benzina et al. demonstrated that deoxypodophyllotoxin extracted from JCo induced apoptosis in breast cancer cells [30] . In addition, Lantto et al. showed that JCo berry extract potentially induced p53-related apoptosis in neuroblastoma cells through inhibition of the PI3K/AKT/mTOR pathway [18] . Therefore, we analyzed the effect of JCo extract on glioblastoma cell proliferation.
In this study, we applied in vitro and in vivo assays to examine the effects of JCo extract on glioblastoma cells. Our results demonstrated that the JCo extract constituents penetrated the BBB to inhibit tumor proliferation and induce cell apoptosis in human glioblastomas.
Materials and Methods

Preparation of plant extract by chloroform and acetone extraction
The roots of Juniperus communis (JCo) were supplied by Chung-Yuan Co. (Taipei, Taiwan). A voucher herbarium specimen was deposited at the School of Pharmacy at the National Defense Medical Center (Taipei, Taiwan). JCo extraction was performed as described previously [19] . A total of 12 kg dried and powdered rhizomes of JCo were extracted three times with acetone (24 L per extraction), three times with chloroform (24 L per extraction), and, then, again with acetone to obtain the plant material. The extract was dissolved in DMSO, incubated with shaking at 25 °C for 1 h and stored at 4 °C before proceeding to further studies.
Cell lines and culture conditions DBTRG-05MG (human GBM), RG2 (rat GBM), SVEC (mouse vascular endothelial cells), and MDCK (mouse kidney cells) were obtained from the American Type Culture Collection (Rockville, MD). In addition, GBM8401, GBM8901, G5T/VGH, and N18 cells were obtained from the laboratory collection of Chung-Shan Medical University. The DBTRG-05MG, GBM8401, GBM8901, G5T/VGH, and N18 cells were cultured in RPMI 1640 at 37 °C in a humidified atmosphere containing 5% CO 2 . The RG2, SVEC, and MDCK cells were cultured in Dulbecco's modified Eagle's medium (DMEM, GIBCO) at 37 °C in a humidified atmosphere containing 5% CO 2 . The media were supplemented with 10% fetal bovine serum (GIBCO, Mexico), 1% sodium pyruvate (GIBCO, USA), 1% HEPES buffer solution (GIBCO, USA), and 1% penicillin/streptomycin (GIBCO, USA).
Analysis of cytotoxicity
To determine the cytotoxicity of the JCo extract, we used a modified 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay to measure cell viability. First, 5 × 10 3 of glioma or normal cells in 100 µL of growth medium were incubated in 96-well plates and grown for 20 h before treatment. Subsequently, 100 µL JCo extract and TMZ were dissolved in medium (500 µg/mL) and added to the cells. After incubation for 24-48 h, the drug-containing medium was replaced with 50 µL fresh medium containing MTT (500 µg/mL) for incubation of 8-12 h. The MTT medium was then removed and 50 µL DMSO was added to each well. The absorbance of the dissolved solutions at 550 nm was detected using an MRX Microtiter Plate Luminometer (DYNEX, Sunnyvale, CA). The absorbance value of untreated control cells was defined as 100% and the IC 50 was defined as the concentration that resulted in a 50% decrease in absorbance in drug-treated cells as compared with that in untreated cells.
Synergistic effects of JCo and TMZ
First, 5 × 10 3 cells/100 µL were placed in each well of a 96-well plate and cultured for 12-18 h until the cells reached 70%-80% confluence. Two types of treatments were performed: group I was treated with 50 µL of TMZ at 0, 20, 40, 80, 120, and 160 µg/mL; and group II was treated with either 50 µL of JCo extract (40 µg/mL) or 50 µL of JCo extract at 0, 10, 20, 40, 60, and 80 µg/mL combined with 50 µL TMZ (80 µg/ mL). After incubation for 24 and 48 h, the MTT assay was performed to analyze cell viability. The synergistic effect was determined from the calculation of the combination index (CI) = (IC 50 of drug combined/ IC 50 of drug only of group I) + (IC 50 of drug combined/ IC 50 of drug only of group II). According to the Chou-Talalay method, the following criteria of drug-drug interactions were considered by CI: synergistic effect, CI < 0.9; additive effect, CI = 0.9-1.1; antagonist effect of drugs, CI > 1.1 [31] . Cell cycle analysis DBTRG-05MG and RG2 (2 × 10 6 cells) were incubated for 18 h and divided into a time course and a drug dosage group. In the time course group, the cell cycle was analyzed at 0, 6, 12, 24, and 48 h after adding 60 µg/mL JCo extract; in the drug dosage group, various concentrations of JCo extract, containing 0, 30, 60, and 90 µg/mL, were examined. The cell cycle status was detected by flow cytometry until 24 h after administration of the JCo extract. Both groups of glioma cells were trypsinized, collected, and washed twice with PBS. The cells were centrifuged at 1000 rpm for 5 min, resuspended in 0.5 mL PBS, fixed in 4.5 mL 70% ice-cold ethanol, and stored at 4 °C. On the day of analysis, the cells were collected by centrifugation and the pellets were resuspended in 0.2 mg/mL propidium iodide containing 0.1% Triton-100 (Sigma) and 1 mg/mL RNase A (Sigma). The cell suspension was incubated in the dark for 30 min at 20 °C±2 °C and subsequently analyzed for DNA content by using a flow cytometer (FACSCalibur; Becton Dickinson, Franklin Lakes, NJ, USA). The percentage of cells in each phase of the cell cycle was calculated using a BD Cell quest computer program. Data were collected from three experiments performed in triplicate.
Terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay to detect cell apoptosis
To evaluate the induction of apoptosis in glioma cells by JCo extract, we used the TUNEL assay (In Situ Cell Death Detection Kit, TUNEL kit, Roche, Germany). Initially, 2 × 10 6 cells were cultured and analyzed at discrete time points (0, 6, 12, 24, and 48 h after 50 µg/mL JCo extract treatment). In the JCo-treated cell group, the suspended cells were collected. In the control group, the adherent and floating cells were collected. The cells were fixed with 3.7% formaldehyde at room temperature for 15 min on silane-coated glass slides. All procedures for the TUNEL assay followed a previously published protocol [19] . After fluorescent staining, we used a fluorescence microscope (Nikon, Kawasaki, Japan) to review the slides and quantify the extent of apoptosis. Finally, we examined the image representative for 48 h JCo extract treatment.
Western blotting analysis
To detect the cell cycle and the apoptosis-related protein expression after JCo extract treatment, we used western blotting. First, 2 × 10 6 DBTRG-05MG and RG2 cells were incubated in a culture dish for 18 h. The cells were collected after the application of 60 µg/mL JCo extract for 0, 6, 12, 24, and 48 h in the timecourse group. To analyze the dose-dependency of the treatment, the cells were collected at 24 h after the addition of 0, 30, 60, and 90 µg/mL JCo extract. All cells were lysed by incubation in RIPA buffer (100 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, and 1% Triton X-100) at 4 °C for 10 min. The crude cell lysates centrifuged at 15, 000 rpm for 10 min to obtain cleared supernatants. Cell lysates (30 µg) from each group were subjected to 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis. The proteins were transferred onto polyvinylidene difluoride (Millipore, MA, USA) and blocked with 5% skim milk in TBST for 1 h at room temperature. After blocking with 5% nonfat milk in TBST (12.5 mM Tris/HCl, pH 7.6, 137 mM NaCl, 0.1% Tween 20), the blots were incubated overnight at 4 °C with the primary antibodies followed by an incubation with the secondary antibody. In this study, the primary antibodies recognized the cell cycle-related proteins cyclin A, cyclin B1, cyclin D1, Cdk2, Cdk4, RB, p-RB, p53, p-p53, p21, and p-p21 (1/200 dilution; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), and the apoptosis-related protein Fas, Fas ligand, caspase-8, Bax, Bcl-2, AIF, caspase-9, and caspase-3 (1/200 dilution; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). The blots were incubated with an appropriate HRP-labeled secondary antibody for 30 min at room temperature, washed extensively, and developed using a T-Pro LumiFast Plus Chemiluminescence Detection Kit (T-Pro BIOTECHNOLOGY, USA) in accordance with the manufacturer's instructions. A monoclonal mouse anti-β-actin antibody (Sigma-Aldrich, St. Louis, MO, USA) was used as the internal control.
Caspase inhibitor assay for detecting apoptotic pathways
To identify the apoptotic pathway of glioma cells treated with JCo extract, the relative protein expression of various subtypes of pro-caspases was detected by western blotting analysis. Initially, 5 × 10 5 DBTRG-05MG and RG2 cells were incubated for 18 h. These cells were divided into four groups: caspaseinhibitor (-)/JCo (-); caspase-inhibitor (+)/ JCo (-); caspase-inhibitor (-)/ JCo (+); and caspase-inhibitor (+)/ JCo (+). The primary antibodies were pro-caspase 8, 9, and 3, and β-actin was used as the internal control.
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Therapeutic effects of JCo in an animal model of subcutaneous tumors
To check the therapeutic effects of JCo extract in an in vivo study, the DBTRG-05MG human GBM cells were used in animal experiments to monitor the antitumor activity. Subcutaneous implantation of 1 × 10 7 cells/100 µL was performed in male Foxn1 nu/nu mice (10-12 weeks old) obtained from the National Laboratory Animal Center (Taipei, Taiwan). The tumor-bearing group and vehicle group of animals were treated with JCo by subcutaneous injection (sc. injection) of 200 mg/kg JCo extract and 5% DMSO, respectively, every 2 days between 5 and 23 days after tumor implantation. The distance between tumor implantation and the JCo sc. injection sites was 2 cm. The animals were sacrificed when the tumor volume exceeded 1, 500 mm 3 or 100 days after inoculation. The tumor volume was calculated as L × H × W × 0.5236 (20) .
Therapeutic effect of JCo in an in-situ glioma model
To detect the therapeutic effects of JCo in animals with brain tumors, the difference in tumor size between the JCo-treated and vehicle-treated rats was examined by MRI. Eight F334 female rats (8-10 weeks old, 150-180 g in weight) were obtained from the National Laboratory Animal Center (Taipei, Taiwan). Initially, 5 × 10 4 RG2 (rat GBM) cells were inoculated in the brain hemisphere of all rats by stereoscope under proper anesthesia. Subsequently, the rats were divided into two equal groups, for administration of either JCo extract or the vehicle. The JCo extract (200 mg/kg with 5% DMSO) was sc. administered daily between day 3 to day 7 after tumor inoculation. In the vehicle group, 5% DMSO was injected into the subcutaneous area at the same time points as the JCo treatment. The tumor volume was measured and calculated by 7-T magnetic resonance imaging (7 Tesla, Bruker BioSpec 70/30 MRI) at National Taiwan University (Taipei, Taiwan) on days 11 and 13 after inoculation of the tumor cells. Finally, the animals were sacrificed when the tumor volume exceeded 1, 500 mm 3 or 100 days after tumor inoculation. Tumor components and some vital organs, including the heart, liver, spleen, lung, kidney, and intestine, were subjected to hematoxylin and eosin (H&E) staining and immunohistochemical (IHC) staining.
H&E staining
For the histological H&E staining of GBM of tumor and normal tissues in the presence or absence of JCo extract, the tissues were fixed in 10% neutral formalin. After the tissues were dehydrated and embedded in paraffin wax, tissue sections (4 µm/section) were placed on clean glass slides and dehydrated in an oven for 30 min at 60 °C. Prior to staining, the tissue slides were deparaffinized, rehydrated, and then stained with Mayer's hematoxylin and eosin Y solution for 3 min.
Immunohistochemistry
To examine the possible mechanism underlying the effect of JCo extract in an in vivo study, we performed IHC staining of angiogenic factors. All tissue sections were de-waxed in xylene, rehydrated in alcohol, and immersed in 3% hydrogen peroxide for 5 min to suppress endogenous peroxidase activity. Antigen retrieval was performed by heating (100 °C) each section for 30 min in 0.01 mol/L sodium citrate buffer (pH 6.0). After three rinses for 5 min each in phosphate-buffered saline [PBS], the sections were incubated for 1 h at room temperature with primary antibodies for anti-PCNA, anti-VEGFR1, anti-VEGFR2, and anti-cleaved caspase-3 (1/200 dilution; Santa Cruz Biotechnology Inc., CA, USA) diluted in PBS. After three washes of 5 min each in PBS, the sections were incubated with biotin-labeled secondary immunoglobulin (1:100, DAKO, Glostrup, Denmark) for 1 h at room temperature. After three additional washes, peroxidase activity was developed by using the 3-amino-9-ethylcarbazole substrate chromogen system (DAKO, Glostrup, Denmark) at room temperature.
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Results
Cytotoxic effects of JCo extract and TMZ on brain tumor and other cell lines
To compare the cytotoxicity of JCo extract and TMZ in tumor and non-tumor cells, we evaluated the IC 50 values in DBTRG-05MG, G5T/VGH, GBM8401, GBM8901, RG2 (glioblastoma cell lines), N18 (neuroblastoma cell line), CTX TNA2 (rat astrocyte cell line), SVEC (vascular endothelial cell line), and MDCK (kidney endothelial cell line). The treatment of the glioblastoma and neuroblastoma cells with JCo extract resulted in various degrees of inhibition of cell viability based on the drug concentration between 24 and 48 h of observation (Fig. 1) . The IC 50 values of JCo extract were 57-69 µg/mL and 49-67 µg/mL in the glioblastoma cell lines after 24 and 48 h, respectively. The respective IC 50 values of JCo extract were 76-105 µg/mL and 77-108 µg/mL in non-tumor cell lines ( Table 1) . The difference in IC 50 values between the tumor and non-tumor cell lines confirmed the safety and efficacy of the drug administration. In contrast, the IC 50 values of TMZ were significantly higher than those of JCo extract at 24 and 48 h, but differences between tumor and nonneoplastic cell lines were not significant. 2A) . In addition, compared to that of the control group (G0/G1: 50.54%; S: 12.61; G2/M: 36.86%), a higher proportion of GBM cells were in the G0/G1 phase (57.48%, 61.29%, 57.58%), and a lower percentage of tumor cells were in the S (7.24%, 6.35%, 8.38%) and G2/M Fig. 1 . The growth inhibition of GBM cells by JCo extract. The tumor cells, which included DBTRG-05MG, RG2, GBM8401, GBM8901, G5T/VGH, and N18, were incubated in 96-well culture plates overnight and treated with JCo extract (0-200 μg/ml) for 24 and 48 h. The cell viability was determined using the MTT assay. Untreated wells were used as control group.
Arrest of cell cycle by JCo extract
Fig. 1
Cell (Fig. 2B) . The degree of cell cycle arrest depended on the level of JCo reaction time and dosage. The western blotting analysis revealed that the JCo extract not only enhanced the expression of tumor suppressor genes, such as p53, phosphorylated p53, and p21, but also inhibited the expression of cell cycle checkpoint proteins, including Rb, CDK2, CDK4, cyclin A, cyclin B1, and cyclin D1 (Fig. 2C) . Therefore, the inhibition of glioblastoma cell proliferation was effectively arrested by administration of JCo extract via the inhibition of the G1-to-S phase checkpoint.
JCo extract triggers GBM cell apoptosis by interacting with intrinsic and extrinsic pathways
The cell cycle analysis indicated that JCo-treated DBTRG-05MG and RG2 glioblastoma cell samples contained a higher percentage of the sub-G1 phase tumor cells (14.03%, 25.93%, 42.06%, 45.60% in DBTRG-05MG cells; 16.22%, 29.36%, 40.39%, 59.30% in RG2 cells) than the control group (2.04%, 1.98%, 1.45%, 2.05% in DBTRG-05MG cells; 6.64%, 6.57%, 6.64%, 6.57% in RG2 cells) at 6, 12, 24, and 48 h (Fig. 3A and 3B ). In the TUNEL test, most of the JCo-treated glioblastoma cells showed a DNA condensation that was detectable using fluorescence microscopy (Fig. 3C) . For the investigation of the apoptotic pathway in glioblastoma cells induced by the JCo extract, the Fas and Fas-L proteins were detected in DBTRG-05MG and RG2 glioblastoma cell lines before and after the JCo treatment. Relative to vehicle-treated glioblastoma cells, JCo-treated tumor cells had higher Fas levels, but lower Fas-L levels after 6 h (Fig. 3D) . The transition from procaspase-8 to activated caspase-8 is a crucial step of the extrinsic apoptotic pathway. The lower expression of procaspase-8 in glioblastoma cells treated with JCo extract suggested the activation of the extrinsic apoptotic pathway. The factors of the intrinsic apoptotic pathway include Bax, Bcl-2, AIF, caspase-3, and caspase-9. Therefore, we performed an immunoblotting experiment to determine if JCo extract activated the extrinsic apoptotic pathway. The protein expression of Bax, AIF, C-caspase-3, and C-caspase-9 was observed in JCo-treated DBTRG-05MG and RG2 was higher in tumor cells than that in non-treated tumor cells. In addition, a reduced expression of Bcl-2 and procaspase 8 and 9 was observed in JCo-treated cells. Moreover, the addition of inhibitors of caspase-3, -8, and -9 in these two glioblastoma cell lines significantly increased procaspase-3, -8, and -9 protein expression. However, the combination of JCo extract and caspase inhibitors might induce the expression of the active forms of caspase-3, -8, and -9 ( Fig. 4A and 4B) . Based on the expression of those factors, we demonstrated that the JCo extract induced glioblastoma apoptosis through both the intrinsic and extrinsic apoptotic pathways. 
Synergistic effects of JCo extract and TMZ in glioblastomas
The JCo extract treatment in the range of 0-45 µg/mL did not inhibit the progression of DBTRG-05MG and RG2 cells. A cytotoxic effect of JCo extract was measured at 60 µg/mL. Higher concentrations of JCo extract caused greater cytotoxicity (Fig. 6A) . TMZ is one of the most common chemotherapeutic agents for glioblastomas. The use of TMZ alone significantly decreased DBTRG-05MG and RG2 tumor cell viability at concentrations above 20 µg/mL. The combination of various concentrations of JCo extract (0-75 µg/mL) with 60 µg/mL TMZ or various doses of TMZ (0-100 µg/mL) with 40 µg/mL JCo extract resulted in a higher percentage of cell apoptosis than those administered with the equivalent concentrations of TMZ or JCo extract alone in DBTRG-05MG and RG2 cells (Fig. 5A and 5B, CI=0.8 and 0.68, respectively). Therefore, the combination of JCo extract with TMZ exerted positive synergistic effects on the inhibition of glioblastoma growth. To identify the pathway through which the combination of JCo extract and TMZ functioned, western blotting analysis of cell proliferative and apoptotic factors was performed. The combination treatment of JCo extract and TMZ downregulated the expression of AKT, mTOR, P70S6K, and their phosphorylated forms, but upregulated that of c-caspase-3, as compared with that of the treatment with either JCo extract or TMZ (Fig. 5C ).
JCo extract effectively inhibits subcutaneous glioblastomas in BALB/c nude mice
To evaluate the in vivo antitumor effects of JCo extract, we injected JCo extract into BALB/c nude mice bearing subcutaneous glioblastomas. The tumor volume was significantly smaller after day 16 in JCo-treated mice than that in vehicle-treated mice. In addition, the tumor size in the vehicle-treated mice was above 1500 mm 3 on day 33, but the volume of all tumors in the JCo-treated mice was below 1300 mm 3 between day 1 and 48 ( Fig. 6A ). All mice that were not treated with JCo were sacrificed on day 31 because of behavioral dysfunction and large tumor volume. In contrast, more than half of the JCo-treated mice survived until day 60 (Fig. 6B) . Therefore, the survival time of JCo-treated nude was longer than that of the vehicle group.
JCo extract significantly inhibits in situ glioblastomas in F344 rats
To detect the ability of the JCo extract to suppress in situ tumor growth, sc. injection of the JCo extract into F344 rats bearing in-situ brain glioblastomas was performed. From the animal MRI images, the tumor sizes of JCo-treated rats measured 6.69 ± 2.48 mm 3 and 12.22 ± 2.43 mm 3 on day 11 and 13, respectively. In contrast, the tumor volumes of vehicle-treated rats measured 58.34 ± 7.35 mm 3 and 96.42 ± 10.74 mm 3 on day 11 and 13, respectively. Therefore, the in situ glioblastomas of JCo-treated rats were significantly smaller than those of the vehicle-treated rats (P < 0.05, Fig. 6C) . Moreover, the survival rate of JCo-treated rats was significantly higher than that of the vehicle-treated rats (Fig. 6D) . The in situ histology analysis identified more apoptotic bodies in the glioblastomas from JCo-treated rats than those in the vehicle-treated rats after animal sacrifice (Fig. 6E) .
Mechanism of suppression of glioblastoma proliferation by JCo extract derived from in vivo analysis
To verify the mechanism of tumor growth inhibition by JCo extract, we performed IHC staining and a TUNEL assay on the in situ inoculated glioblastomas. In all rats with in situ glioblastomas, the labeling index of PCNA, VEGFR1, VEGFR2, c-caspase 3 were 73.08%, 9.67%, 11.70%, 2.43% in vehicle group of tumors respectively. However, in the JCo-treated glioblastomas, 44.49%, 5.88%, 5.85% and 6.53% of tumor cells had increased levels of PCNA, VEGFR1, VEGFR2 and c-caspase 3. Therefore, the JCo-treated glioblastomas had a significantly lower expression of PCNA, VEGFR1, and VEGFR2, but a higher expression of c-caspase-3 as compared to those of the vehicle-treated glioblastomas (Fig. 7A) . In addition, the TUNEL test showed that the group with JCo-treated intracranial glioblastomas had a higher percentage of apoptotic cells than those of the vehicle-treated glioblastomas (Fig. 7B) . 
Physiologic and pathologic toxicity of JCo extract in the in vivo analysis
To verify the toxicity of the JCo extract in other nonneoplastic organs, the data from the blood analysis and the internal organs of the experimental nude mice and rats were collected. Neither inflammatory cell aggregation nor cellular apoptosis in the heart, liver, spleen, lung, kidney, and intestine was identified by histological analysis of tissues from JCo extracttreated and vehicle-treated animals (Fig. 8) . In addition, the serum levels of red blood cells (RBC), platelets (PLT), hemoglobin (HGB), hematocrit (HCT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and creatinine (CRE) also showed no significant difference between tissues from JCo-treated and vehicle-treated animals (Fig. 9 ). In addition, we also checked the platelet function and other immune cell kinetics at 12 and 24 h because of the limited number of blood samples. In all test for coagulative functions, PT (prothrombin time) and APTT (activated partial thromboplastin time) were analyzed. The average PT in the JCo-treated glioma rats was 15.6 ± 1.9 s and 15.8 ± 2.1 s at 12 and 24 h, respectively. The PT in the vehicle-treated glioma rats was 15.7 ± 2.2 s and 15.9 ± 2.0 s at 12 and 24 h, respectively. In addition, the averages of APTT in the JCo-treated and the vehicle-treated glioma rats were 22.2 ± 1.7 s and 22.8 ± 2.2 s at 12 h and 22.7 ± 2.4 s and 23.0 ± 2.1 s at 24 h, respectively. Therefore, analysis of the coagulative functions showed no differences between the two treatment groups of rats. In addition, the CD4/CD8 ratio of T cells and the levels of interleukin-1 beta (IL-1β) and tumor necrotic factor-alpha (TNF-α) were evaluated in the JCo-treated and vehicle-treated animals at 12 and 24 h. However, there was no statistically significant difference between the two treatment groups. Fig. 8 . JCo extract showed low or no physiological and pathological toxicity in vivo. Mice, at 10-12 weeks of age, were treated with vehicle (n=5) and 200 mg/kg JCo extract (n=5) by sc. injection every 2 days for 10 times. After sacrificing the animals, the organs (heart, liver, spleen, lung, kidney, intestine and stomach) were collected and analyzed for damage by H&E staining. Cellular Physiology and Biochemistry cell lines, the cytotoxic effect of JCo extract was stronger than that of other chemotherapeutic agents [32] . Unfortunately, the hypothesis of the suppression of in situ brain glioma by JCo extract still lacks compelling evidence. This study is the first to demonstrate that the JCo extract can penetrate the BBB to induce brain glioma cell apoptosis by sc. injection of JCo extract.
In our in vitro studies, the IC 50 values of the JCo extract in all GBM cell lines were significantly lower than those in normal astrocytes and endothelial cell lines after both 24 and 48 h. However, the IC 50 values of TMZ indicated an overlap of cytotoxic concentrations in some GBM cell lines and normal astrocytes and endothelial cells. In addition, the IC 50 values of the JCo extract were also lower than those of TMZ in GBM cell lines. Compared with TMZ, the JCo extract induced stronger cytotoxic effects with greater specificity for GBM cells. To explore the mechanism of inhibition of GBM cells by the JCo extract, we used flow cytometric analysis to demonstrate that cell cycle arrest might play an important role in the cytotoxicity of JCo-treated GBM cells. The overexpression of tumor suppressor genes, such as p53, and the inhibition of cell-proliferation related proteins, such as Rb, supported a possible antitumor activity of the JCo extract. Interestingly, the cyclin/CDK family is known to be essential for cell replication, especially CDK2, CDK4, and cyclin-A, -B, -D, and -E [33] . In contrast, p21 acts as an inhibitor for CDK proteins [33] . The JCo extract effectively blocked GBM cells in the G0/G1 phase from entering the S and G2/M phase by exerting control over the cell cycle checkpoints, causing an inhibition or delay in GBM cell replication.
The degree of tumor apoptosis may be an important factor for selecting new anticancer drugs for development [34] . The higher percentage of sub-G1 phase tumor cells after drug treatment could be an indicator for a greater degree of cellular apoptosis. Using fluorescence microscopy, the TUNEL test highlighted DNA fragmentation and the condensation of tumor cells [35, 36] . The results from our two examinations demonstrated that JCo extract significantly induced GBM cell apoptosis. Furthermore, a higher concentration of JCo extract appeared to more effective in inducing cytotoxicity in GBM cells. The mechanism of cellular apoptosis can be divided into the intrinsic and the extrinsic pathway [37] . The indicative factors of the extrinsic apoptotic pathway include Fas ligand (Fas-L), Fas receptor, cleaved caspase-8, and cleaved caspase-3 [38] . The BAX/BAK system and apoptotic protease activating factor-1 (APAF-1) are the main factors of the intrinsic apoptotic pathway [34] . Bcl2/Bcl-XL acts as an antagonist for BAX [39] . Our study is the first to demonstrate that the treatment with JCo extract caused DNA damage in GBM cells and induced apoptosis via the intrinsic and the extrinsic pathway.
TMZ is a widely used chemotherapeutic drug for patients with recurrent and highly aggressive astrocytoma, especially for patients with GBM [40] . A possible serious complication of TMZ is the suppression of hematopoiesis, which can induce aplastic anemia, bleeding, and immunodeficiency [41] . In this study, the therapeutic effect observed with the combination of the JCo extract with TMZ was a more effective treatment than the effect observed using either of these two therapeutics as single treatment. The synergistic effect of JCo extract and TMZ could allow a reduced the dosage of TMZ, which would reduce the incidence of serious complications, such as bone marrow suppression. In addition, the interaction of the mTOR and PI3K pathways is a central regulator of the cellular proliferative signal transduction that induces tumor cell survival and angiogenesis [42, 43] . Akt, mTOR, and p70S6 expression could activate those pathways and induce a phosphorylation cascade that stimulates cell growth. In this study, we successfully demonstrated that the synergistic effects of a combination of the JCo extract and TMZ inhibited GBM proliferation by blocking Akt, mTOR, and p70S6 expression.
In our in vivo studies, the subcutaneous tumor size was significantly smaller in JCotreated mice than that in vehicle-treated mice. A larger proportion of tumor apoptosis was also observed in the JCo-treated mice than in the vehicle-treated mice. In addition, because the BBB can cause the dysfunction of a chemotherapeutic drug, we established an in situ GBM animal model and sc. injected JCo extract to examine if the JCo extract could penetrate the BBB. Importantly, the MRI and histological analysis indicated that the JCo extract Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry could effectively inhibit in situ brain tumor proliferation and induce cell apoptosis. To our knowledge, we have presented the first study published in English that the JCo extract could penetrate the intratumoral BBB. GBM-induced angiogenesis is essential for tumor cell proliferation and invasion [44] . The apoptosis of GBM cells results from radiotherapy and chemotherapy, which induces hypoxia in the tumor microenvironment that enhances platelet-derived growth factor subunit B (PDGF-B) and/or epidermal growth factor (EGF) receptor expression [45] . In contrast, some antivascular therapeutic drugs may induce perivascular GBM cell invasion, which may result in the resistance to second-line therapies [46, 47] . In our study, a lower expression of VEGFR-1 and -2 and a higher expression of cleaved caspase-3 were observed in the JCotreated mice with in situ GBM tumors than in the vehicle-treated groups, which indicated that the JCo extract not only inhibited intratumoral angiogenesis, but also induced tumor cell apoptosis. In contrast, low functional and histological damage to non-neoplastic vital organs should be the most important requirement for the development of new drugs. The histological analysis demonstrated that most of the vital organs in JCo-treated rats, including the heart, liver, kidney, lung, intestine, and spleen, had a similar microscopic appearance as those in vehicle-treated animals. In addition, no significant differences in blood cell count, the serum levels of hepatic enzyme, and renal function index were identified between JCotreated and vehicle-treated animals. Therefore, the pharmacological effects of the JCo extract appeared to be specific for GBM cells and did not affect other non-neoplastic vital organs, which confirmed the safety of this new herbal therapy.
Conclusion
In this study, we successfully demonstrated that the JCo extract appears to be a safe herbal therapeutic that effectively suppressed glioma cell proliferation by inhibiting angiogenesis. In addition, a combination of JCo extract and TMZ exerted synergistic effects to induce tumor apoptosis. Therefore, JCo extract may represent a beneficial therapeutic choice for high-grade gliomas.
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